Katharyn L Flickinger, Alexandra Weissman, Jonathan Elmer, Patrick J Coppler, Francis X Guyette, Melissa J Repine, Cameron Dezfulian, David Hopkins, Adam Frisch, Ankur A Doshi, Jon C Rittenberger, Clifton W Callaway
{"title":"代谢操纵和治疗性低温。","authors":"Katharyn L Flickinger, Alexandra Weissman, Jonathan Elmer, Patrick J Coppler, Francis X Guyette, Melissa J Repine, Cameron Dezfulian, David Hopkins, Adam Frisch, Ankur A Doshi, Jon C Rittenberger, Clifton W Callaway","doi":"10.1089/ther.2023.0010","DOIUrl":null,"url":null,"abstract":"<p><p>Hypothermia has multiple physiological effects, including decreasing metabolic rate and oxygen consumption (VO<sub>2</sub>). There are few human data about the magnitude of change in VO<sub>2</sub> with decreases in core temperature. We aimed to quantify to magnitude of reduction in resting VO<sub>2</sub> as we reduced core temperature in lightly sedated healthy individuals. After informed consent and physical screening, we cooled participants by rapidly infusing 20 mL/kg of cold (4°C) saline intravenously and placing surface cooling pads on the torso. We attempted to suppress shivering using a 1 mcg/kg intravenous bolus of dexmedetomidine followed by titrated infusion at 1.0 to 1.5 μg/(kg·h). We measured resting metabolic rate VO<sub>2</sub> through indirect calorimetry at baseline (37°C) and at 36°C, 35°C, 34°C, and 33°C. Nine participants had mean age 30 (standard deviation 10) years and 7 (78%) were male. Baseline VO<sub>2</sub> was 3.36 mL/(kg·min) (interquartile range 2.98-3.76) mL/(kg·min). VO<sub>2</sub> was associated with core temperature and declined with each degree decrease in core temperature, unless shivering occurred. Over the entire range from 37°C to 33°C, median VO<sub>2</sub> declined 0.7 mL/(kg·min) (20.8%) in the absence of shivering. The largest average decrease in VO<sub>2</sub> per degree Celsius was by 0.46 mL/(kg·min) (13.7%) and occurred between 37°C and 36°C in the absence of shivering. After a participant developed shivering, core body temperature did not decrease further, and VO<sub>2</sub> increased. In lightly sedated humans, metabolic rate decreases around 5.2% for each 1°C decrease in core temperature from 37°C to 33°C. Because the largest decrease in metabolic rate occurs between 37°C and 36°C, subclinical shivering or other homeostatic reflexes may be present at lower temperatures.</p>","PeriodicalId":22972,"journal":{"name":"Therapeutic hypothermia and temperature management","volume":" ","pages":"46-51"},"PeriodicalIF":0.8000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Metabolic Manipulation and Therapeutic Hypothermia.\",\"authors\":\"Katharyn L Flickinger, Alexandra Weissman, Jonathan Elmer, Patrick J Coppler, Francis X Guyette, Melissa J Repine, Cameron Dezfulian, David Hopkins, Adam Frisch, Ankur A Doshi, Jon C Rittenberger, Clifton W Callaway\",\"doi\":\"10.1089/ther.2023.0010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Hypothermia has multiple physiological effects, including decreasing metabolic rate and oxygen consumption (VO<sub>2</sub>). There are few human data about the magnitude of change in VO<sub>2</sub> with decreases in core temperature. We aimed to quantify to magnitude of reduction in resting VO<sub>2</sub> as we reduced core temperature in lightly sedated healthy individuals. After informed consent and physical screening, we cooled participants by rapidly infusing 20 mL/kg of cold (4°C) saline intravenously and placing surface cooling pads on the torso. We attempted to suppress shivering using a 1 mcg/kg intravenous bolus of dexmedetomidine followed by titrated infusion at 1.0 to 1.5 μg/(kg·h). We measured resting metabolic rate VO<sub>2</sub> through indirect calorimetry at baseline (37°C) and at 36°C, 35°C, 34°C, and 33°C. Nine participants had mean age 30 (standard deviation 10) years and 7 (78%) were male. Baseline VO<sub>2</sub> was 3.36 mL/(kg·min) (interquartile range 2.98-3.76) mL/(kg·min). VO<sub>2</sub> was associated with core temperature and declined with each degree decrease in core temperature, unless shivering occurred. Over the entire range from 37°C to 33°C, median VO<sub>2</sub> declined 0.7 mL/(kg·min) (20.8%) in the absence of shivering. The largest average decrease in VO<sub>2</sub> per degree Celsius was by 0.46 mL/(kg·min) (13.7%) and occurred between 37°C and 36°C in the absence of shivering. After a participant developed shivering, core body temperature did not decrease further, and VO<sub>2</sub> increased. In lightly sedated humans, metabolic rate decreases around 5.2% for each 1°C decrease in core temperature from 37°C to 33°C. Because the largest decrease in metabolic rate occurs between 37°C and 36°C, subclinical shivering or other homeostatic reflexes may be present at lower temperatures.</p>\",\"PeriodicalId\":22972,\"journal\":{\"name\":\"Therapeutic hypothermia and temperature management\",\"volume\":\" \",\"pages\":\"46-51\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic hypothermia and temperature management\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/ther.2023.0010\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/7/3 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic hypothermia and temperature management","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/ther.2023.0010","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/3 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
Metabolic Manipulation and Therapeutic Hypothermia.
Hypothermia has multiple physiological effects, including decreasing metabolic rate and oxygen consumption (VO2). There are few human data about the magnitude of change in VO2 with decreases in core temperature. We aimed to quantify to magnitude of reduction in resting VO2 as we reduced core temperature in lightly sedated healthy individuals. After informed consent and physical screening, we cooled participants by rapidly infusing 20 mL/kg of cold (4°C) saline intravenously and placing surface cooling pads on the torso. We attempted to suppress shivering using a 1 mcg/kg intravenous bolus of dexmedetomidine followed by titrated infusion at 1.0 to 1.5 μg/(kg·h). We measured resting metabolic rate VO2 through indirect calorimetry at baseline (37°C) and at 36°C, 35°C, 34°C, and 33°C. Nine participants had mean age 30 (standard deviation 10) years and 7 (78%) were male. Baseline VO2 was 3.36 mL/(kg·min) (interquartile range 2.98-3.76) mL/(kg·min). VO2 was associated with core temperature and declined with each degree decrease in core temperature, unless shivering occurred. Over the entire range from 37°C to 33°C, median VO2 declined 0.7 mL/(kg·min) (20.8%) in the absence of shivering. The largest average decrease in VO2 per degree Celsius was by 0.46 mL/(kg·min) (13.7%) and occurred between 37°C and 36°C in the absence of shivering. After a participant developed shivering, core body temperature did not decrease further, and VO2 increased. In lightly sedated humans, metabolic rate decreases around 5.2% for each 1°C decrease in core temperature from 37°C to 33°C. Because the largest decrease in metabolic rate occurs between 37°C and 36°C, subclinical shivering or other homeostatic reflexes may be present at lower temperatures.
期刊介绍:
Therapeutic Hypothermia and Temperature Management is the first and only journal to cover all aspects of hypothermia and temperature considerations relevant to this exciting field, including its application in cardiac arrest, spinal cord and traumatic brain injury, stroke, burns, and much more. The Journal provides a strong multidisciplinary forum to ensure that research advances are well disseminated, and that therapeutic hypothermia is well understood and used effectively to enhance patient outcomes. Novel findings from translational preclinical investigations as well as clinical studies and trials are featured in original articles, state-of-the-art review articles, protocols and best practices.
Therapeutic Hypothermia and Temperature Management coverage includes:
Temperature mechanisms and cooling strategies
Protocols, risk factors, and drug interventions
Intraoperative considerations
Post-resuscitation cooling
ICU management.